Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.

McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.

Osteoporos Int. 2013 Jan;24(1):301-10. doi: 10.1007/s00198-012-2175-7. Epub 2012 Oct 19.

2.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.

Osteoporos Int. 2013 Jan;24(1):293-9. doi: 10.1007/s00198-012-2056-0. Epub 2012 Jun 30.

3.

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.

McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR.

Osteoporos Int. 2012 Jan;23(1):267-76. doi: 10.1007/s00198-011-1791-y. Epub 2011 Sep 27.

4.

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.

Clin Ther. 2009 Feb;31(2):272-85. doi: 10.1016/j.clinthera.2009.02.012.

PMID:
19302900
5.

Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.

Racewicz AJ, Schofield PJ, Cahall DL, Cline GA, Burgio DE.

Curr Med Res Opin. 2007 Dec;23(12):3079-89.

PMID:
17971285
6.

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S.

Bone. 2008 Jan;42(1):36-42. Epub 2007 Sep 8.

PMID:
17920005
7.

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.

Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE.

J Bone Miner Res. 2005 Dec;20(12):2105-15. Epub 2005 Aug 22.

8.

Inhibition of brain choline uptake by isoarecolone and lobeline derivatives: implications for potential vector-mediated brain drug delivery.

Metting TL, Burgio DE, Terry AV Jr, Beach JW, McCurdy CR, Allen DD.

Neurosci Lett. 1998 Dec 11;258(1):25-8.

PMID:
9876043
9.

Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution.

Burgio DE, Gosland MP, McNamara aPJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):911-7.

10.

Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis.

Burgio DE, Gosland MP, McNamara PJ.

Biochem Pharmacol. 1996 Apr 12;51(7):987-92.

PMID:
8651950
11.

Pharmacokinetics of caffeine and its demethylated metabolites in lactation: predictions of milk to serum concentration ratios.

Oo CY, Burgio DE, Kuhn RC, Desai N, McNamara PJ.

Pharm Res. 1995 Feb;12(2):313-6. No abstract available.

PMID:
7784352
12.

Phenobarbital disposition in adult and neonatal rabbits.

Yoo SD, Burgio DE, McNamara PJ.

Pharm Res. 1994 Aug;11(8):1204-6. No abstract available.

PMID:
7971725
13.

Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis.

Yokel RA, Allen DD, Burgio DE, McNamara PJ.

J Pharmacol Toxicol Methods. 1992 May;27(3):135-42.

PMID:
1498341

Supplemental Content

Loading ...
Support Center